SCHEMBL22013781

SCHEMBL22013781

CC(C)C(=O)c1cccc(-c2ccccn2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 2/20 0.49
CTSL P07711 2/20 0.47
CTSK P43235 1/20 0.47
CNR1 P21554 1/20 0.47
CYP2A6 P11509 1/20 0.46
CTSB P07858 1/20 0.46
CTSS P25774 1/20 0.46
KDM4E B2RXH2 2/20 0.45
KDM6B O15054 1/20 0.45
KDM4A O75164 1/20 0.45
KDM5C P41229 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
KDM2A Q9Y2K7 1/20 0.45
KDM3A Q9Y4C1 1/20 0.45
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
TLR4 O00206 1/20 0.43
TLR2 O60603 1/20 0.43
SCN9A Q15858 1/20 0.43
GRM5 P41594 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13687394 0.87 CLK4 (0.46) KAT6AKDM4EABL1DBHGAA
SCHEMBL17742695 0.81 MAP4K4 (0.55) KAT6ACNR1CYP2A6KDM4EKDM6B
SCHEMBL30937997 0.81 MAP4K4 (0.55) KAT6ACNR1CYP2A6KDM4EKDM6B
SCHEMBL10276830 0.81 KMO (0.60) KDM4EGRM5DBHGAARECQL
SCHEMBL5108635 0.81 KAT6A (0.55) KAT6ACNR1CYP2A6KDM4EKDM6B
SCHEMBL22677182 0.81 KAT6A (0.50) KAT6ACNR1KDM4EKDM6BKDM4A
SCHEMBL207017 0.80 KDM4E (0.69) KAT6ACNR1CYP2A6KDM4EKDM6B
SCHEMBL2457556 0.80 KAT6A (0.54) KAT6ACNR1CYP2A6KDM4EKDM6B
SCHEMBL29800516 0.80 KDM4E (0.69) KAT6ACNR1CYP2A6KDM4EKDM6B
SCHEMBL167080 0.78 CHEK2 (0.57) KAT6ACNR1CYP2A6KDM4EKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10662183-B2 Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662183-B2 Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same SREBF1, SREBF2, BPTF KAT6A 292/4885CTSL 3830/4885CTSK 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.